Kivizidiale

Timolol, the active ingredient in Kivizidiale, is a beta blocker / prostaglandin analog combination presented as an ophthalmic solution (eye drops) for ocular (topical) use. It treats open-angle glaucoma and ocular hypertension in adults. GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is used to manage intraocular pressure in conditions affecting the eye's drainage pathways. - Open‑angle glaucoma: reduces intraocular pressure to slow optic nerve damage. - Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Primary open‑angle glaucoma: maintains target pressure to preserve visual field.

Kivizidiale may cause ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Conjunctival hyperemia (red eye). - Dry eye or foreign‑body feeling.

Serious or Rare Side Effects: - Allergic eye reaction with swelling or severe redness. - Sudden loss of vision or marked eye pain. - Increased intraocular pressure despite therapy. - Systemic beta‑blocker effects such as bradycardia or bronchospasm.

Before prescribing Kivizidiale, clinicians should evaluate patient‑specific risk factors. - Cardiovascular assessment: monitor for bradycardia or hypotension. - Respiratory status: avoid in patients with asthma or severe COPD. - Ocular surface disease: use with caution in severe dry eye or corneal disorders. - Hypersensitivity: discontinue if allergic reaction occurs. - Concomitant ocular drugs: assess for additive pressure‑lowering effects. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Kivizidiale can interact with other medications that affect ocular or systemic beta‑adrenergic pathways.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: may cause additive bradycardia or hypotension. - Concurrent prostaglandin analog eye drops: increase risk of ocular inflammation.

Moderate Interactions (Monitor Closely): - Topical NSAIDs: may exacerbate corneal irritation. - Systemic antihypertensives: monitor blood pressure for additive lowering. - Other intraocular pressure‑lowering agents: adjust dosing to avoid over‑reduction of pressure.